Reading LXEO? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track LXEO free→Reading LXEO? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track LXEO free→NASDAQHealth CareBiotechnologySnapshot 2026-06-15
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
Recent financial performance is neutral, and management's recent track record has been fairly steady. The company was unprofitable over the past year, so its earnings quality can't be assessed, and it has a capital-unfriendly stance. Risk is elevated, and the sector backdrop is a headwind, which may impact performance compared to peers. The read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 0 valuation methods, at three horizons. Current price $4.65. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Not enough valuation methods to set a 12-month read yet.
TTM earnings are negative, so the read leans on sales- and cash-flow-based methods rather than P/E. This is a data condition, not a forward call.
Not enough peers to compare yet.
Self-history needs ~20 months of data.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 50% of the time over the next year (vs 57% for the rest of the cohort, n=3115).
Over the trailing year it converted 1.12x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, Fed net liquidity, real (inflation-adjusted) rates, long-term interest rates.
9 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated neutral grew net income 58% of the time over the next year (vs 50% for the rest of the cohort, n=842).
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $-0.31 → $-0.28 (+10.2% / 30d). 3 raised, 0 cut, 6 covering analysts.
0 upgrades, 0 downgrades / 30d. 100% of analysts rate Buy.
0 positive, 1 negative / 30d. See F4 management tile for the event list.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$294.
How much price usually moves either way.
On a bad day, this stock has moved -$704.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $6,115.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-15
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
No named catalysts to watch right now. Check back after the next earnings report.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for LXEO yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Other Events. On June 15, 2026, Lexeo Therapeutics, Inc. (the "Company") issued a press release a nnouncing the regulatory updates to LX2006 for the treatment of Friedreich ataxia (FA) cardiomyopathy including the pivotal study design to support accelerated approval. As part of the pre ss release, the Company announced that it would be hosting a conference call and webcast at 8:00 a.m. ET on June 15, 2026 to discuss regulatory updates on LX2006 for the treatment of FA cardiomyopathy. The pres…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
No score history yet for this stock.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Biotechnology.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
LXEO Lexeo Therapeutics, Inc. | — | — | elevated |
ABBV AbbVie | Above typical Show detailsSector percentile: 85 of 100 | fair | low |
AMGN Amgen | Above typical Show detailsSector percentile: 78 of 100 | full | moderate |
GILD Gilead Sciences | Above typical Show detailsSector percentile: 100 of 100 | fair | moderate |
VRTX Vertex Pharmaceuticals | Above typical Show detailsSector percentile: 80 of 100 | expensive | moderate |
Not investment advice. As of 2026-06-15.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-15.
Maintain cash, cash equivalents, and investments to support operations into 2028.
Stated in 2 of last 2 quarters. Cash, cash equivalents, and investments decreased from $246.6 million in 2025-Q4 to $227.6 million in 2026-Q1. Despite the decrease, management maintains that the operational runway extends into 2028, indicating a focus on capital preservation. The trajectory shows limited progress in maintaining cash levels.
“Cash, cash equivalents and investments of $227.6 million expected to provide operational runway into 2028.”
“Cash, cash equivalents and investments of $246.6 million expected to provide operational runway into 2028.”
Provide regulatory updates on LX2006 for the treatment of Friedreich ataxia cardiomyopathy.
Newly stated in 2026-Q2. Management announced regulatory updates for LX2006, indicating a focus on advancing this treatment for Friedreich ataxia cardiomyopathy. No financial metrics directly tied to this priority were disclosed, making it difficult to assess substantive progress beyond the announcement.
“Announced regulatory updates to LX2006 for the treatment of Friedreich ataxia cardiomyopathy.”
and Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any of the Company’s filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such a filing.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (d) Appointment of New Director On April 28, 2026 (the “ Appointment Date ”), Dr. Laura Sepp-Lorenzino was appointed to the board of directors (the “ Board ”) of Lexeo Therapeutics, Inc. (the “ Company ”). Dr. Sepp-Lorenzino will serve as a director with a term of office expiring at the Company’s 2028 Annual Meeting of Stockholders. As of the Appoi…
and Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any of the Company’s filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such a filing.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment of Chief Operating Officer On January 27, 2026, Lexeo Therapeutics, Inc. (the “Company”) announced that the Board of Directors of the Company (the “Board”) appointed Jose Manuel Otero, Ph.D., the Company’s current Chief Technical Officer, to serve as Chief Operating Officer of the Company, effective as of January 2, 2026. For Dr. Otero’…